Presenter: Cynthia Bye, ND and Charissa Bausch, ND

Original Date: March 20, 2022

• Variety of Gynecological cancers
• Possible factors of causation
• Choices of care- overview of phases of care
• Co-management during standard of Care and drugs relevant and possible responses: Nausea, Pancytopenia, Neuropathy, Cardiotoxicity, Hepatotoxicity
• Specific Issues relevant to Gynecological Cancers
• Complexities of reproduction and reproduction seasons and age cycles

Remission retention/survivorship/long term care,

• Address causative factors and long-term side effects of treatment
• Common causative factors/drivers
• Side effects

ii. Modulation of carcinogenic drivers.

• No Evidence of disease
• Those that still have cancer after standard of care
• Other lifestyle concerns and issues.

Pharma covered Alkeran (Melphalan),Avastin Bevacizumab)Bevacizumab, Carboplatin Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Doxil (Doxorubicin Hydrochloride Liposome, Doxorubicin Hydrochloride Liposome, Gemcitabine Hydrochloride, Hycamtin (Topotecan Hydrochloride), Infugem (Gemcitabine Hydrochloride), Lynparza (Olaparib), Melphalan, Niraparib Tosylate,Monohydrate, Olaparib, Paclitaxel, Paraplatin (Carboplatin), Rubraca (Rucaparib Camsylate, Rucaparib Camsylate, Tepadina (Thiotepa), ThiotepaTopotecan Hydrochloride, Zejula (Niraparib Tosylate Monohydrate)

1.0 General and 0.5 Pharmacology (Total 1.5 CEUs) approved by OBNM